


**IN THE CLAIMS:**

The present listing of claims replaces all other listings of the claims.

1. (Previously presented) A compound of formula I



I

or a pharmaceutically acceptable salts, hydrates or optical isomers of said compound, wherein:

A<sup>1</sup>, A<sup>2</sup>, A<sup>3</sup> and A<sup>4</sup> are independently hydrogen, C<sub>1</sub>-C<sub>9</sub> alkyl, C<sub>2</sub>-C<sub>9</sub> alkenyl, C<sub>2</sub>-C<sub>9</sub> alkynyl, aryl, heteroaryl, carbocycle, heterocycle, C<sub>1</sub>-C<sub>9</sub> alkoxy, C<sub>2</sub>-C<sub>9</sub> alkenyloxy, phenoxy, benzyloxy, hydroxy, halo, nitro, cyano, isocyano, -COOR<sup>6</sup>, -COR<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -SOR<sup>6</sup>, -SO<sub>2</sub>R<sup>6</sup>, -SO<sub>2</sub>(OR<sup>6</sup>), -(C=O)NR<sup>6</sup>R<sup>7</sup>, -(C=O)NR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>COOH, -NR<sup>6</sup>(C=O)R<sup>7</sup> or -(CH<sub>2</sub>)<sub>n</sub>COOH, or any adjacent two of A<sup>1</sup>, A<sup>2</sup>, A<sup>3</sup> and A<sup>4</sup> form with the benzene ring a fused ring that is saturated or unsaturated, aromatic or non-aromatic, and carbocyclic or heterocyclic, said heterocyclic ring containing 1 or 2 oxygen, nitrogen and/or sulfur heteroatom(s);

n is 1-3;

R, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are independently hydrogen, carboxy, C<sub>1</sub>-C<sub>9</sub> alkyl, C<sub>2</sub>-C<sub>9</sub> alkenyl, C<sub>2</sub>-C<sub>9</sub> alkynyl, aryl, heteroaryl, carbocycle or heterocycle; and

said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle, alkoxy, alkenyloxy, phenoxy, benzyloxy and fused ring are independently unsubstituted or substituted with one or more substituent(s).

2. (Original) The compound of claim 1, wherein:

A<sup>1</sup>, A<sup>2</sup>, A<sup>3</sup> and A<sup>4</sup> are independently hydrogen or -COOH;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each hydrogen; and

R<sup>5</sup> is hydrogen, phenyl, benzyl or phenylethyl, wherein said phenyl, benzyl and phenylethyl are independently unsubstituted or substituted with one or more substituent(s).

3. (Original) The compound of claim 2, wherein R<sup>5</sup> is benzyl substituted with one or more substituent(s) independently selected from the group consisting of carboxy, halo, C<sub>1</sub>-C<sub>4</sub> alkyl and C<sub>1</sub>-C<sub>4</sub> alkoxy.

4. (Previously presented) The compound of claim 1, wherein said compound is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;  
1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.

5. (Original) The compound of claim 1, wherein said compound is an enantiomer or an enantiomer-enriched mixture.

6 to 44 (Canceled)

45. (Original) A pharmaceutical composition comprising:

- (i) an effective amount of a compound of claim 1; and
- (ii) a pharmaceutically acceptable carrier.

46. (Previously presented) The pharmaceutical composition of claim 45, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;  
1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.

47. (Previously presented) The pharmaceutical composition of claim 45, wherein:

A<sup>1</sup>, A<sup>2</sup>, A<sup>3</sup> and A<sup>4</sup> are independently hydrogen or -COOH;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each hydrogen; and

R<sup>5</sup> is hydrogen, phenyl, benzyl or phenylethyl, wherein said phenyl, benzyl or phenylethyl are independently substituted with one or more substituent(s).

48. (Previously presented) The pharmaceutical composition of claim 47, wherein R<sup>5</sup> is benzyl substituted with one or more substituent(s) independently selected from the group consisting of carboxy, halo, C<sub>1</sub>-C<sub>4</sub> alkyl and C<sub>1</sub>-C<sub>4</sub> alkoxy.

49. (Previously presented) The pharmaceutical composition of claim 45, wherein the compound is an enantiomer or an enantiomer-enriched mixture.

50. (New) A method for inhibiting NAALADase enzyme activity in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of claim 1.

51. (New) The method of claim 50, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;  
1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid; and  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.

52. (New) A method for treating a glutamate abnormality in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of claim 1.

53. (New) A method of claim 52, wherein the glutamate abnormality is selected from the group consisting of compulsive disorder, spinal cord injury, epilepsy, stroke, ischemia, demyelinating disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis ("ALS"), Huntington's disease, schizophrenia, pain, peripheral neuropathy, traumatic brain injury, neuronal insult, inflammatory disease, anxiety, anxiety disorder, memory impairment, glaucoma and retinal disorder.

54. (New) The method of claim 53, wherein the retinal disorder is retinopathy, age-related macular degeneration.

55. (New) The method of claim 52 wherein the glutamate abnormality is compulsive disorder.

56. (New) The method of claim 55, wherein the compulsive disorder is selected from the group consisting of drug dependence and eating disorder.

57. (New) The method of claim 56, wherein the drug dependence is alcohol dependence, nicotine dependence or cocaine dependence.

58. (New) The method of claim 52, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;

1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.

59. (New) A method for effecting a neuronal activity in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of claim 1.

60. (New) The method of claim 59, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of a neurological disorder.

61. (New) The method of claim 60, wherein the neurological disorder is selected from the group consisting of trigeminal neuralgia, glossopharyngeal neuralgia, Bell's Palsy, myasthenia gravis, muscular dystrophy, progressive muscular atrophy, progressive bulbar inherited muscular atrophy, herniated, ruptured or prolapsed invertebrate disk syndromes, cervical spondylosis, plexus disorders, thoracic outlet and destruction syndromes.

62. (New) The method of claim 60, wherein the neurological disorder is selected from the group consisting of neuropathy, pain, traumatic brain injury, physical damage to spinal cord, stroke associated with brain damage, demyelinating disease and neurological disorder relating to neurodegeneration.

63. (New) The method of claim 62, wherein said neuropathy is peripheral neuropathy or diabetic neuropathy.

64. (New) The method of claim 62, wherein said pain is neuropathic pain.

65. (New) The method of claim 64, wherein said compound is administered in combination with an effective amount of morphine.

66. (New) The method of claim 62, wherein the neurological disorder relating to neurodegeneration is Alzheimer's disease.

67. (New) The method of claim 62, wherein the neurological disorder relating to neurodegeneration is Parkinson's disease.

68. (New) The method of claim 62, wherein the neurological disorder relating to neurodegeneration is Huntington's disease.

69. (New) The method of claim 62, wherein the neurological disorder relating to neurodegeneration is ALS.

70. (New) The method of claim 59, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;

1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;

1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;

1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and

1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.

71. (New) A method for treating a prostate disease in a mammal is need thereof, comprising administering to said mammal an effective amount of a compound of claim 1.

72. (New) The method of claim 71, wherein the prostate disease is prostate cancer.

73. (New) The method of claim 71, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;

1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;

1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;

3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;



1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic  
acid.

74. (New) A method for treating cancer in a mammal in need thereof, comprising  
administering to said mammal an effective amount of a compound of claim 1.

75. (New) The method of claim 74, wherein said cancer is of the brain, kidney or  
testis.

76. (New) The method of claim 74, wherein said the compound of claim 1 is selected  
from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;  
1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-  
carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic  
acid.

77. (New) A method for inhibiting angiogenesis in a mammal in need thereof comprising administering to said mammal an effective amount of a compound of claim 1.

78. (New) The method of claim 77, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;  
1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.

79. (New) A method for effecting a TGF- $\beta$  activity in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of claim 1.

80. (New) The method of claim 79, wherein said effecting a TGF- $\beta$  activity is increasing, reducing or regulating TGF- $\beta$  levels, or treating a TGF- $\beta$  abnormality.

81. (New) The method of claim 80, wherein said effecting a TGF- $\beta$  activity is treating a TGF- $\beta$  abnormality, and said TGF- $\beta$  abnormality is neurodegenerative disorder, extra-cellular

matrix formation disorder, cell-growth related disease, infectious disease, immune related disease, epithelial tissue scarring, collagen vascular disease, fibroproliferative disorder, connective tissue disorder, inflammation, inflammatory disease, respiratory distress syndrome, infertility or diabetes.

82. (New) The method of claim 79, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;  
1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.

83. (New) A method for detecting a disease, disorder or condition where NAALADase levels are altered, comprising:

(i) contacting a sample of bodily tissue or fluid with an effective amount of a compound of claim 1, wherein said compound binds to any NAALADase in said sample; and

(ii) measuring the amount of any NAALADase bound to said sample, wherein the amount of NAALADase is diagnostic for said disease, disorder or condition.

84. (New) The method of claim 83, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;  
1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.

85. (New) A method for detecting a disease, disorder or condition where NAALADase levels are altered in a mammal, comprising:

- (i) labeling a compound of claim 1 with an effective amount of an imaging reagent;
- (ii) administering to said mammal an effective amount of the labeled compound;
- (iii) allowing said labeled compound to localize and bind to NAALADase present in said mammal; and
- (iv) measuring the amount of NAALADase bound to said labeled compound, wherein the amount of NAALADase is diagnostic for said disease, disorder or condition.

86. (New) The method of claim 85, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;  
1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.

87. (New) A diagnostic kit for detecting a disease, disorder or condition where NAALADase levels are altered, comprising a compound of claim 1 labeled with a marker.

88. (New) The diagnostic kit of claim 87, wherein said the compound of claim 1 is selected from the group consisting of:

3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1H-indole-2,7-dicarboxylic acid;  
1-[(3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-bromo-5-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(phenylmethyl)-1H-indole-2-carboxylic acid;

1-[(2-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(4-bromo-3-carboxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
1-[(2-carboxy-5-methoxyphenyl)methyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-phenyl-1H-indole-2-carboxylic acid;  
3-(2-mercaptoethyl)-1-(2-phenylethyl)-1H-indole-2-carboxylic acid;  
1-(3-carboxyphenyl)-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid; and  
1-[3-carboxy-5-(1,1-dimethylethyl)phenyl]-3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid.